Dr. Anand Prakash Singh is a Research Investigator at the Frankel Cardiovascular Center, Michigan Medicine, Ann Arbor, where he leads translational studies in cardio-oncology, cardio-immunology, heart failure with preserved ejection fraction (HFpEF), and exercise-induced cardiac regeneration. He earned his B.Sc. in Chemistry, Botany, and Zoology from the University of Lucknow (2007), M.Sc. in Biotechnology from the University of Allahabad, and Ph.D. in Molecular Medicine from Jawaharlal Nehru University, New Delhi. Following his doctorate, he completed postdoctoral training at prestigious institutions including South Asian University, Vanderbilt University Medical Center, the University of Alabama at Birmingham, and Massachusetts General Hospital/Harvard Medical School, while also serving as a visiting scholar at the Broad Institute of MIT and Harvard. His research focuses on understanding the molecular pathways of cardiac inflammation, senescence, and regeneration, particularly in the context of metabolic stress and cancer therapy–induced cardiotoxicity. Dr. Singh is the recipient of multiple competitive grants, including the Frankel Cardiovascular Center Inaugural Grant Award and VA IPA funding, and has contributed as Co-Investigator to major NIH and AHA projects exploring heart–brain interactions and exercise-mediated cardioprotection. Recognized for his scholarly excellence, he has received honors such as the First Prize for Oral Presentation at the International Conference on Innovation & Technologies in Medicine and Healthcare and the Outstanding Reviewer Award from Experimental Biology and Medicine. His ongoing research aims to bridge basic molecular mechanisms with clinical therapeutics for cardiovascular disease prevention and recovery.
Profile: Google Scholar
Featured Publications
Guo, H. L. Y., Gupte, M., Umbarkar, P., Singh, A. P., et al. (2017). Entanglement of GSK-3β, β-catenin and TGF-β1 signaling network to regulate myocardial fibrosis. Journal of Molecular and Cellular Cardiology, 174, Article 107–118.
Singh, A. P., Glennon, M. S., Umbarkar, P., Gupte, M., Galindo, C. L., Zhang, Q., et al. (2019). Ponatinib-induced cardiotoxicity: Delineating the signalling mechanisms and potential rescue strategies. Cardiovascular Research, 115(5), 966–977.
Umbarkar, P., Tousif, S., Singh, A. P., Anderson, J. C., Zhang, Q., Tallquist, M. D., et al. (2022). Fibroblast GSK-3α promotes fibrosis via RAF-MEK-ERK pathway in the injured heart. Circulation Research, 131(7), 620–636.
Singh, A. P., Umbarkar, P., Tousif, S., & Lal, H. (2020). Cardiotoxicity of the BCR-ABL1 tyrosine kinase inhibitors: Emphasis on ponatinib. International Journal of Cardiology, 316, 214–221.
Umbarkar, P., Singh, A. P., Gupte, M., Verma, V. K., Galindo, C. L., Guo, Y., Zhang, Q., et al. (2019). Cardiomyocyte SMAD4-dependent TGF-β signaling is essential to maintain adult heart homeostasis. JACC: Basic to Translational Science, 4(1), 41–53.
Tousif, S., Singh, A. P., Umbarkar, P., Galindo, C., Wheeler, N., Toro Cora, A., et al. (2023). Ponatinib drives cardiotoxicity by S100A8/A9-NLRP3-IL-1β mediated inflammation. Circulation Research, 132(3), 267–289.